Ilaprazole

Generic Name
Ilaprazole
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C19H18N4O2S
CAS Number
172152-36-2
Unique Ingredient Identifier
776Q6XX45J
Background

Ilaprazole has been investigated in Helicobacter Infections.

Indication

用于治疗十二指肠溃疡及反流性食管炎。

Associated Conditions
-
Associated Therapies
-

Effects of Ilaprazole on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone ESD.

Phase 4
Completed
Conditions
Interventions
First Posted Date
2015-12-23
Last Posted Date
2020-07-31
Lead Sponsor
Il-Yang Pharm. Co., Ltd.
Target Recruit Count
176
Registration Number
NCT02638584
Locations
🇰🇷

HALLYM UNIVERSITY MEDICAL CENTER, Chuncheon Sacred Heart Hospital, Chuncheon, Gangwon-do, Korea, Republic of

Efficacy/Safety Study as H. Pylori Eradication of Triple Therapy for 7 Days Treatment

Phase 3
Completed
Conditions
Interventions
First Posted Date
2014-03-12
Last Posted Date
2014-06-03
Lead Sponsor
Il-Yang Pharm. Co., Ltd.
Target Recruit Count
323
Registration Number
NCT02084420
Locations
🇰🇷

Kangbuk Samsung Hospital, Seoul, Korea, Republic of

🇰🇷

Seoul Asan hoapital, Seoul, Korea, Republic of

🇰🇷

Inje Busan Paik Hospital, Busan, Korea, Republic of

and more 15 locations

Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety

First Posted Date
2013-03-28
Last Posted Date
2013-03-28
Lead Sponsor
Il-Yang Pharm. Co., Ltd.
Target Recruit Count
40
Registration Number
NCT01820143
Locations
🇨🇦

MDS Pharma Services, Québec, Canada

Pharmacokinetic/Pharmacodynamic Study of Ilaprazole to Evaluate the Effect of CYP Genetic Polymorphism

Phase 1
Completed
Conditions
Interventions
First Posted Date
2012-09-20
Last Posted Date
2012-09-20
Lead Sponsor
Inje University
Target Recruit Count
27
Registration Number
NCT01688544
Locations
🇰🇷

Inje University Busan Paik Hoapital Clinical Trial Center, Busan, Korea, Republic of

Efficacy Study of Ilaprazole to Treat Erosive Esophgitis

Phase 3
Completed
Conditions
Interventions
First Posted Date
2012-01-12
Last Posted Date
2012-01-12
Lead Sponsor
Il-Yang Pharm. Co., Ltd.
Target Recruit Count
292
Registration Number
NCT01509261
Locations
🇰🇷

Local Institution, Seoul, Korea, Republic of

Safety and Efficacy of Ilaprazole 5, 20 and 40 mg QD and Lansoprazole 30 mg QD on Healing of Erosive Esophagitis

Phase 2
Completed
Conditions
Interventions
First Posted Date
2007-05-09
Last Posted Date
2012-02-02
Lead Sponsor
Takeda
Target Recruit Count
831
Registration Number
NCT00471094
© Copyright 2024. All Rights Reserved by MedPath